This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Abstract Details
Activity Number:
|
329
|
Type:
|
Topic Contributed
|
Date/Time:
|
Tuesday, August 3, 2010 : 10:30 AM to 12:20 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract - #306334 |
Title:
|
Scaled Average Bioequivalence for Highly Variable Drugs
|
Author(s):
|
Scott Patterson*+ and Byron Jones and Dieter Hauschke
|
Companies:
|
Pfizer Inc. and Pfizer Inc. and University Medical Center Freiburg
|
Address:
|
500 Arcola Rd, Collegeville, PA, 19425,
|
Keywords:
|
bioequivalence ;
scaled ;
average ;
geometric mean ;
simulation
|
Abstract:
|
The two-one sided test procedure (TOST) has been used for average bioequivalence testing since 1992 and is required when marketing new formulations of an approved drug. TOST is known to require comparatively large numbers of subjects to demonstrate bioequivalence for highly variable drugs, defined as those drugs having intra-subject coefficients of variation greater than 30%, but has been shown to protect public health when multiple generic formulations enter the market. Recently, scaled average bioequivalence (SABE) has been proposed as an alternative to TOST. Following a brief summary of SABE design and analysis methods, we will consider the statistical ramifications of the proposed point estimate decision rule and the potential impact of implementation of scaled average bioequivalence in the marketplace using simulation.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2010 program
|
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.